What’s New with Tumor Markers for Colorectal Cancer?

Abstract

Background/Aims: Many tumor markers have been utilized in the follow-up care of colorectal cancer patients. No marker, however, has proven reliably accurate in detecting recurrent disease. Methods: The strengths and weaknesses of currently available tumor markers are reviewed, with attention to related cost and efficacy. Results: Tumor antigens, enzymes, and genetic markers have been used as tumor markers. CEA and CA 19.9 are the most widely utilized; however, genetic markers are the most promising for the future. Conclusions: Currently available markers have significant limitations. Development of genetic markers may greatly enhance our ability to predict prognosis and the need for adjuvant therapy. Marker-guided therapy may play an increasing role in this disease.